Negative Expression of DSG1 and DSG2, as Prognostic Biomarkers, Impacts on the Overall Survival in Patients with Extrahepatic Cholangiocarcinoma

Table 1

Correlations of DSG1 and DSG2 protein expression with the clinicopathological characteristics of EHCC.

CPC	Case no.	DSG1			DSG2
		Pos No. (%)		value	Pos No. (%)		Value
Age (year)
≤45 years	17	8 (47.1)	0.215	0.643	9 (52.9)	0.290	0.590
>45 years	83	34 (41.0)			38 (45.8)
Sex
Male	61	27 (44.3)	0.329	0.566	29 (47.5)	0.018	0.892
Female	39	15 (38.5)			18 (46.2)
Differentiation
Well	31	24 (77.4)	23.142	0.000	25 (80.6)	6.434	0.040
Moderately	34	9 (26.5)			11 (32.4)
Poorly	35	9 (25.7)			11 (31.4)
Tumour size
≤3 cm	62	27 (43.5)	0.161	0.689	29 (46.8)	0.003	0.954
>3 cm	38	15 (39.5)			18 (47.4)
Tumour position
Hilar site	27	10 (37.0)	0.990	0.609	12 (44.4)	0.991	0.609
Hepatic duct	4	1 (25.0)			1 (25.0)
Distal duct	69	31 (44.9)			34 (49.3)
Bile stone
No	69	33 (47.8)	3.101	0.078	36 (52.2)	2.392	0.122
Yes	31	9 (29.0)			11 (35.5)
Lymphnode metastasis
No	62	38 (61.3)	24.924	0.000	39 (62.9)	16.566	0.000
Yes	38	4 (10.5)			8 (21.1)
Invasion
No	33	22 (66.7)	12.320	0.000	22 (66.7)	7.648	0.006
Yes	67	20 (29.2)			25 (37.3)
TNM stage
I+II	35	23 (65.7)	21.460	0.000	26 (74.3)	27.598	0.000
III	38	17 (44.7)			19 (50.0)
IV	27	2 (7.4)			2 (7.4)
Surgery
Radical	54	32 (59.3)	15.078	0.001	36 (66.7)	19.220	0.000
Palliative	36	9 (25.0)			10 (27.8)
Biopsy	10	1 (10.0)			1 (80.0)

DSG1: desmoglein 1; DSG2: desmoglein 2; EHCC: extrahepatic cholangiocarcinoma; Pos No.: positive number.